SENORES share price, P/E, ROE & financials

Senores Pharmaceuticals (SENORES) had a P/E of 38.1× on 6 Nov 2026, above the industry P/E of 37.3×, and the shares are 27% below their 52-week high. Sales and net profit grew 159% and 139% a year over 3 years, with ROCE of 16% and ROE of 15%. Debt is 0.40× equity. It is a small-cap company with a market cap of ₹5,347 Cr, ranked 9th of 15 Drug Manufacturers (General) companies by market cap; the shares rose 55% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year

Open: ₹1,185.00
Day high: ₹1,185.00
Day low: ₹1,130.10
Prev. close: ₹1,187.90
Volume: 2.7 L

Health check

3 good · 2 fair · 1 to check

ReturnsIn line
+54.9% over a year, better than 4 of 7 peers.
Price tagIn line
P/E 38.1 vs industry 37.3.
GrowthStrong
Sales +159.0%, profit +139.1% a year over 3 years.
ProfitabilityWeak
ROCE 15.5% vs peer median 23.3%.
Balance sheetSolid
Debt 0.40× equity, interest covered 7.7×, Piotroski 6 of 9.
Red flagsNone found
No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - General

14 listed peers. Screen the industry

Small cap

₹5,347 Cr, #9 of 15 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹719 Cr · profit ₹133 Cr

Market cap: ₹5,347 Cr; Small cap
P/E: 38.1; Industry 37.3
Price to book: 5.17; Peers 18.55
Dividend yield: 0.00%
ROE: 14.7%; Peers 20.9%
ROCE: 15.5%; Peers 23.3%
Debt to equity: 0.40; Debt ₹417 Cr
EPS (TTM): ₹30.45; Face value ₹10
OPM (TTM): 29.9%; Net margin 18.6%
Sales growth: +24.9%; Latest quarter vs a year ago
Profit growth: +22.0%; Latest quarter vs a year ago
Price to sales: 7.44; EV/EBITDA 27.2

Strengths

Quarterly profit up 22.0% on a year ago.
Quarterly sales up 24.9% on a year ago.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Senores Pharmaceuticals

Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, neurology, antacid, and vitamin and mineral preparation…

Headquarters: Ahmedabad
Employees: 368
Sector: Healthcare
ISIN: INE0RB801010
Website: senorespharma.com

Price range

52 weeks

₹706.00₹1,599.00

Today

₹1,130.10₹1,185.00

Avg volume (3M): 2.9 L
1-year return: plus 54.9%
From 52-week high: minus 27.4%

Analyst consensus

5 analysts

Strong buyMean target ₹1,571.60 35.4%

Target range, with today’s price

Low ₹1,500.00High ₹1,700.00

Today’s price ₹1,161.00 is below the lowest analyst target.

Consensus from Yahoo Finance. Not a recommendation.

Peers · Drug Manufacturers - General

Compare with peers Screen the whole industry

Company
GLAXOGlaxosmithkline Pharmaceuticals	2,524.80	plus 0.98%	42,772	37.3	22.73	55.4%	63.9%	34.1%	5.7%	19.3%	2.26%	minus 6.0%
RUBICONRubicon Research	1,659.30	minus 4.67%	27,468	95.6	19.38	23.6%	19.1%	23.3%	–	–	0.09%	plus 166.7%
PFIZERPfizer	3,856.00	minus 0.02%	17,640	23.2	4.02	22.9%	20.9%	36.7%	1.3%	5.0%	1.94%	minus 24.6%
CORONACORONA Remedies	2,441.10	plus 2.58%	14,930	72.1	18.55	29.0%	28.3%	21.3%	16.6%	29.7%	0.41%	plus 69.7%
MARKSANSMarksans Pharma	303.70	minus 3.20%	13,764	24.6	4.13	17.5%	15.2%	22.5%	16.7%	16.2%	0.30%	plus 68.0%
SYMBIOTECSymbiotec Pharmalab	1,513.60	plus 19.04%	9,726	103.5	8.26	14.3%	11.2%	10.7%	16.8%	67.3%	0.00%	plus 37.9%
SANOFICONRSanofi Consumer Healthcare India	3,420.20	minus 0.69%	7,888	28.2	22.64	–	80.4%	37.8%	–	–	2.19%	minus 29.5%
SENORESSenores Pharmaceuticals	1,161.00	minus 2.26%	5,347	38.1	5.17	15.5%	14.7%	24.6%	159.0%	139.1%	0.00%	plus 54.9%
Median of 7 peers	–	−0.02%	14,930	37.3	18.55	23.3%	20.9%	23.3%	16.6%	19.3%	0.41%	37.9%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
154	165	175	180	192
112	111	128	126	135
41.7	54	47.5	53.8	57.7
27.1%	32.8%	27.1%	29.8%	30.0%
13.2	3.8	17.7	2.8	8.9
6.2	5.3	8.5	7.2	8.8
8.1	7.9	9.3	9.9	10.3
40.6	44.6	47.4	39.5	47.6
25.9%	24.7%	22.6%	22.8%	23.1%
32.4	31.7	31.6	30.7	39.5
6.54	7.29	7.96	6.60	8.82

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +159.0%
Profit CAGR 3Y: +139.1%
EPS CAGR 3Y: +143.3%
ROE: 14.7%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
35.3	211	381	614
–	+496.7%	+80.6%	+61.4%
22.7	169	291	441
12.7	41.8	89.8	173
35.9%	19.8%	23.6%	28.1%
3.4	1.7	18.1	45.2
1.8	8.5	20.4	23.9
1.8	10	16.8	31.3
−0	−0	−0.1	−3.7
12.4	24.9	70.6	159
32.2%	−31.1%	17.3%	23.6%
8.4	31.5	58.6	115
–	+272.9%	+86.2%	+97.0%
1.83	6.83	16.12	26.39

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
9.8	30.5	46.1	46.1
35.7	174	740	888
62.6	258	315	342
23	160	126	328
131	622	1,227	1,604
16.2	182	260	366
9	20.8	51.6	20.8
0.4	19.5	1.3	6.2
0.1	12.9	386	160
105	387	529	1,051
131	622	1,227	1,604

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
−1.1	−25.7	−45.9	62.1
−48.3	−54.2	−429	−121
46.3	87	573	−1.3
−3.1	7.1	97.7	−59.8
−47.3	−51.8	−158	−265
−48.4	−77.5	−203	−203

Shareholding pattern

Source: NSE filings

45.8%

promoters

Promoters45.82%
Public54.18%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	45.82%	54.18%	0.00
30 Jun 2026	45.82%	54.18%	0.00
31 Mar 2026	45.82%	54.18%	plus 0.02
31 Dec 2025	45.80%	54.20%	0.00
30 Sep 2025	45.80%	54.20%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you